Face-to-Face: Allon targets tau pathology with lead drug davunetide
This article was originally published in Scrip
Executive Summary
As Allon Therapeutics prepares to advance its lead drug candidate, davunetide intranasal (formerly AL-108), into proof-of-concept trials for progressive supranuclear palsy (PSP), its chief medical officer, Dr Steven Whitaker told Scrip of the company's excitement at its potential as a treatment for the rare indication – one of the types of frontotemporal dementia (FTD) for which there are currently no US FDA-approved therapies.